US sen­a­tors, ac­tivists chas­tise Gilead­'s Tru­va­da pric­ing, spot­light­ing CDC patents on drug's use as HIV pre­ven­tion pill

Once up­on a time, Gilead was the pur­vey­or of im­pos­si­bly high-priced, but fan­tas­ti­cal­ly ef­fec­tive, he­pati­tis C drugs. Now at­ten­tion has turned to its HIV pill, Tru­va­da, which the CDC re­port­ed­ly has some patents on. In a let­ter to the HHS, a cadre of US sen­a­tors un­der­scored their con­cern that the drug — which is ap­proved to pre­vent HIV — could be in­fring­ing up­on gov­ern­ment patents and is be­ing sold at a price that makes it un­af­ford­able for many Amer­i­cans.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER